| Filed On | Filing |
|---|---|
| 02 Nov 2026 |
8-K: Results of Operations and Financial Condition
— Achieved total revenue of $3.44 billion, a 12% increase compared to third quarter 2025 — |
| 20 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
(d) On October 20, 2026, Daniel Brennan was appointed as a new member of the board of directors (the “Board”) of Vertex Pharmaceuticals Incorporated (the “Company”). In connection with the appointment of Mr. Brennan, the size of the Boar... |
| 01 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On August 27, 2026, Vertex Pharmaceuticals Incorporated (the “Company”) appointed Jonathan Poole as Executive Vice President and Chief Financial Officer of the Company, effective January 1, 2027 (the “Effective Date”). In connection with... |
| 03 Aug 2026 |
8-K: Results of Operations and Financial Condition
— Total revenue of $3.33 billion, a 12% increase compared to second quarter 2025 — |
| 07 Jul 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure +1 more
Exhibit 99.1 VERTEX PHARMACEUTICALS ACQUISITION OF CRINETICS PHARMACEUTICALS July 6, 2026 Presentation intended for the investment community ©2026 Vertex Pharmaceuticals Incorporated ©2026 Vertex Pharmaceuticals Incorporated |
| 13 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
On March 27, 2026, the Board of Directors (the "Board") of Vertex Pharmaceuticals Incorporated (the "Company") approved the Vertex Pharmaceuticals Incorporated 2026 Stock and Option Plan (the "2026 Plan"), which replaces the Vertex Pharm... |
| 04 May 2026 |
8-K: Results of Operations and Financial Condition
— Total revenue of $2.99 billion, an 8% increase compared to first quarter 2025 — |
| 29 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On April 28, 2026, Suketu Upadhyay informed the board of directors (the “Board”) of Vertex Pharmaceuticals Incorporated (the “Company”) of his decision not to stand for re-election as a director of the Company at the Company’s 2026 annua... |
| 31 Mar 2026 |
8-K: Other Events
Vertex Pharmaceuticals Incorporated (the “Company”) has completed the submission to the U.S. Food and Drug Administration (the “FDA”) of its rolling Biologics Licensing Application (“BLA”) for potential accelerated approval of povetacice... |
| 12 Feb 2026 |
8-K: Results of Operations and Financial Condition
— Full year total revenue of $12.0 billion, a 9% increase compared to full year 2024; fourth quarter total revenue of $3.19 billion, a 10% increase compared to fourth quarter 2024 — |
| 03 Nov 2025 |
8-K: Results of Operations and Financial Condition
— Total revenue of $3.08 billion, an 11% increase compared to Q3 2024 — |
| 04 Aug 2025 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
— Total revenue of $2.96 billion, a 12% increase compared to Q2 2024; reiterated full year 2025 financial guidance, including revenue guidance of $11.85 to $12 billion — |
| 19 May 2025 |
8-K: Other Events
The Board of Directors of Vertex Pharmaceuticals Incorporated (the “Company”) has authorized an additional program to repurchase up to $4.0 billion of the Company’s common stock (the “2025 Repurchase Program”). The 2025 Repurchase Progra... |
| 14 May 2025 |
8-K: Submission of Matters to a Vote of Security Holders
The annual meeting of shareholders of Vertex Pharmaceuticals Incorporated (the "Company") was held on May 14, 2025 (the "Annual Meeting"). Set forth below are the voting results for each of the proposals submitted to a vote of the Compan... |
| 05 May 2025 |
8-K: Results of Operations and Financial Condition
— Total revenue of $2.77 billion, a 3% increase compared to Q1 2024; raised the low end of total revenue guidance by $100 million to a new range of $11.85 to $12 billion — |
| 28 Mar 2025 |
8-K: Other Events
On March 28, 2025, Vertex Pharmaceuticals Incorporated (“Vertex”) announced several updates to its type 1 diabetes portfolio, including results from the Phase 1/2 clinical trial evaluating VX-264, which will not be advancing further in c... |
| 10 Feb 2025 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
— Full year product revenue of $11.02 billion, a 12% increase compared to full year 2023 — |
| 20 Dec 2024 |
8-K: Regulation FD Disclosure
On December 20, 2024, the U.S. Food and Drug Administration approved ALYFTREK™ (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis in people 6 years and older who have at least one F508del mutation or another muta... |
| 04 Nov 2024 |
8-K: Results of Operations and Financial Condition
— Product revenue of $2.77 billion, a 12% increase compared to Q3 2023 — |
| 16 Aug 2024 |
8-K: Entry into a Material Definitive Agreement
On August 15, 2024, Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Vertex"), and SNH Seaport LLC, a Delaware limited liability company, entered into amendments (the "Headquarters Lease Amendments") to Vertex's leases ... |
Loading...